Related Experiment Videos
Pathogenesis and treatment perspectives of chronic graft rejection (CVR)
1Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Insights
Chronic rejection threatens transplant survival, marked by graft vessel remodeling and function decline. Novel therapies like angiopeptin and carvedilol show promise in managing this complex condition.
Area of Science:
- Transplantation immunology
- Cardiovascular research
- Nephrology
Background:
- Chronic rejection is a primary cause of long-term graft failure in heart and kidney transplantation.
- It involves graft vascular remodeling, parenchymal damage, and progressive loss of organ function.
- The underlying pathogenesis is complex and multifactorial, necessitating optimized immunosuppression.
Purpose of the Study:
- To review current understanding and potential therapeutic strategies for chronic rejection in organ transplantation.
- To explore novel pharmacological agents targeting the mechanisms of chronic rejection.
- To identify promising candidates for future clinical investigation.
Main Methods:
- Literature review of existing studies on chronic rejection.
- Analysis of experimental data on novel therapeutic agents.
- Evaluation of pharmacological interventions affecting prostaglandin metabolism, lipid profiles, and oxidative stress.
Main Results:
- Current immunosuppressive strategies require optimization.
- Agents like omega-3 fatty acids and heparin derivatives have shown preliminary efficacy.
- Angiopeptin and carvedilol demonstrate significant potential based on experimental findings.
Conclusions:
- There are no established methods for preventing or treating chronic rejection.
- Emerging therapies targeting vascular remodeling, oxidative stress, and inflammation are promising.
- Carvedilol, with its multifaceted properties, represents a strong novel candidate for managing chronic rejection.
Abstract:
Chronic rejection is a major threat towards the long-term function and survival of transplanted hearts and kidneys. It is characterized by a proliferative remodelling of the graft vessels along with structural changes of the parenchyma and gradual deterioration of graft function. The pathogenesis is complex and multifactorial. Since grafts with chronic rejection are also subjected to a more or less intense invasion of immunoreactive cells, an important primary objective is to optimize the immunosuppressive treatment. There is no established means of prevention or treatment of chronic rejection. Pharmacological agents interfering with prostaglandin metabolism have been tried most frequently and preliminary results are also available from the use of polyunsaturated fatty acids of the omega-3 series and of heparin derivatives. Based on experimental studies the somatostatin analogue angiopeptin seems very promising today. There will certainly be an increased interest in the use of lipid-reducing agents in the future as well as antioxidant agents acting against the effects of reactive oxygen radicals and oxidative modification of LDL fractions. A strong novel candidate is carvedilol, exerting both antihypertensive, antioxidant and antiproliferative properties.